Capiton buys CNP Group

CNP's management team and a number of industry experts have also invested in the company, according to a statement.

Capiton plans to increase CNP's Germany-based production capacity, as well as support its international expansion.

The deal is the first from Capiton's sixth fund, which held a first close in Q2 2020, as reported by Unquote. The fund is targeting €550m.

Company
CNP produces generic pharmaceutical products, focusing on anti-infectives, as well as antibiotics, over-the-counter medicines and medical devices. Based in Fürstenzell, CNP has operations in 19 countries. It has revenues of €40m and employs 250 people.

People
Capiton – Alexander Zamora (investment director); Jonathan Lerman (associate); Martin Gwashavanhu (analyst).

Advisers
Equity – Hampton Pharma (commercial due diligence); Fidelio Healthcare Partners (commercial due diligence); PwC (corporate finance); EY (tax); BMH (legal); Straeter Rechtsanwaelte (legal); Dr Regenold (regulatory and technical due diligence); Willis Tower Watson (insurance due diligence); AvS (management due diligence); Tauw (ESG due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany
• capiton AG